Alpha, beta and gamma cyclodextrin differ only in how many glucose units form the ring – six, seven and eight – and that single number decides which guest molecules each can hold. The choice is usually presented as a solubility question, which is misleading: solubility decides whether your process is practical, but cavity size decides whether complexation happens at all. Get the order wrong and you buy a very expensive excipient that does nothing.
1. The three natives, side by side
| Property | α-Cyclodextrin | β-Cyclodextrin | γ-Cyclodextrin |
|---|---|---|---|
| CAS | 10016-20-3 | 7585-39-9 | 17465-86-0 |
| Glucose units | 6 | 7 | 8 |
| Formula / MW (anhydrous) | C36H60O30 / 972.8 | C42H70O35 / 1135.0 | C48H80O40 / 1297.1 |
| Cavity diameter | 4.7-5.3 Å | 6.0-6.5 Å | 7.5-8.3 Å |
| Water solubility (25 °C) | About 145 g/L | About 18.5 g/L | About 232 g/L |
| Specific rotation (typical) | About +150° | +159° to +164° | About +177° |
| Cost per kilogram | Highest of the three | Lowest of the three | Intermediate to high |
Notice the inverted relationship: β-cyclodextrin is the cheapest and the least soluble. That is not a coincidence – it is the least soluble precisely because its seven-unit ring packs into a more rigid, less hydrated crystal, and the same economics that make it cheap to crystallise make it hard to dissolve.
2. First question: does the guest fit?
| Guest type | Effective size | Homologue that fits |
|---|---|---|
| Small volatiles, short-chain acids and alcohols, some flavour notes | Small | α-cyclodextrin – a β cavity would be too loose to retain them |
| Most drug-like molecules, vitamins, essential-oil components, many actives | Medium | β-cyclodextrin |
| Steroids, larger terpenes, some peptides and macrolides | Large | γ-cyclodextrin – they simply will not enter a β cavity |
Two failure modes follow directly. A guest that is too small for the cavity forms a loose complex that releases immediately, so the protection you paid for never materialises. A guest that is too large never enters, and no increase in cyclodextrin loading will change that. Both present as “the cyclodextrin did not work” and both are answered by changing the homologue, not the dose.
3. Second question: can you reach the concentration you need?
Once the cavity fits, the constraint becomes the amount of complex the process can carry. Because β-cyclodextrin dissolves only to about 18.5 g/L, a formulation that needs a high concentration of complexed guest will hit the solubility ceiling before it hits the stoichiometric one.
| Situation | Practical answer |
|---|---|
| Low-dose guest, complex needed at a few grams per litre | β-cyclodextrin works and is the cheapest option |
| High-dose guest, or a concentrate that must stay clear | Move to a β-derivative – the parent will not dissolve enough |
| Guest is small and volatile | α-cyclodextrin, despite the higher cost |
| Guest is bulky | γ-cyclodextrin, or a derivative if the dose is high as well |
| Solid dosage form, complex isolated as a powder | β-cyclodextrin – the low solubility is an advantage during isolation |
This is why the poor solubility of β-cyclodextrin is not simply a defect: in a solid dosage form you want the complex to crystallise out, and a freely soluble cyclodextrin is harder to isolate.
4. When a derivative is the right answer
| Derivative | Why it exists | Where it is used |
|---|---|---|
| Hydroxypropyl-β-cyclodextrin (HP-β-CD) | Freely soluble; the substitution breaks up the crystal lattice that limits the parent compound | Oral and topical pharmaceutical formulations, some cosmetic uses |
| Sulfobutyl ether β-cyclodextrin (SBE-β-CD, as the sodium salt) | Freely soluble, and better tolerated for parenteral use | Injectable formulations |
| Methylated and other substituted β-cyclodextrins | Tailored solubility and surface activity | Specialty pharmaceutical and formulation work |
Substitution does not change the cavity much, so a derivative is chosen for solubility and tolerability, not to fit a different guest. And because the degree of substitution varies between manufacturers, these products are described by their substitution range rather than by a single CAS – the specification, not the CAS, is what you are buying.
5. The regulatory asymmetry that overrides everything
This is the point most often missed in a technical comparison: the natives and the derivatives do not share a regulatory status, and a decision that ignores this cannot be implemented.
| Material | Food use | Pharmaceutical use |
|---|---|---|
| β-cyclodextrin | Has a food additive identity (E459) for specified uses, subject to national rules and use levels | Pharmacopoeial monograph exists; widely used as an excipient |
| α- and γ-cyclodextrin | Status differs by market and is generally narrower – check before assuming | Pharmacopoeial monographs exist for some |
| HP-β-CD and SBE-β-CD | Generally not food ingredients | Well established as excipients, including parenteral use for SBE |
A formulator who solves the solubility problem with a derivative and then discovers that the derivative is not permitted in the intended food application has solved the wrong problem. Regulatory fit has to be checked before the technical comparison, not after.
6. Choosing, in order
- Establish the regulatory envelope for the destination market and the intended use.
- Confirm the guest fits – test the candidate homologue experimentally; do not infer from molecular weight alone.
- Determine the stoichiometry of the complex, because 2:1 systems change the cost calculation completely.
- Check the achievable concentration against the homologue’s solubility, and move to a derivative only if you must.
- Only then compare prices, on a cost-per-mole-of-complex basis rather than per kilogram of cyclodextrin.
7. Four mistakes worth avoiding
- Choosing β-cyclodextrin because it is cheapest, then finding the guest does not fit.
- Choosing a derivative for solubility without checking that it is permitted in the application.
- Assuming 1:1 stoichiometry when the guest is small – small guests often form 2:1 complexes, doubling the cyclodextrin cost.
- Comparing specifications across homologues: an assay of 98-102% on a hydrate means something different from a 98% figure on an anhydrous derivative.
8. Packaging and supply
All three natives ship as white crystalline powders in 25 kg drums or lined bags, with sealed development packs available. They are hydrates, so storage humidity shifts the loss-on-drying figure – keep them sealed, cool and dry. Derivatives generally ship as powders too, but check the specification for the substitution range and the water content, since those, not a CAS number, define the material. Every lot is supplied with a COA and SDS, FOB or CIF against destination, and a pharmacopoeial compliance statement where the application requires one.
Related reading
- Beta-cyclodextrin: properties, inclusion chemistry and applications
- Cyclodextrin in food and pharmaceutical use: E459, pharmacopoeial status and what to verify
- Beta-cyclodextrin (CAS 7585-39-9) – product page
PolyBlueChem supplies β-cyclodextrin (CAS 7585-39-9) and can source the alpha and gamma homologues and the substituted β-cyclodextrins to specification, with per-batch COA and SDS and FOB/CIF delivery. Tell us the guest molecule, the required concentration and the destination market, and we will confirm the homologue that fits both the cavity and the regulation.